Crown Biosciences looks destined to go unworn for a while longer after its planned $204 million acquisition by China's Adicon fell through.
In a Nov. 16 announcement, the CEO of Crown's parent JSR revealed that the parties decided to terminate the agreement “as the conditions precedent to closing were not expected to be satisfied within the originally anticipated timeframe."
In its own disclosure (PDF) to the Hong Kong Stock Exchange, Adicon noted that the transaction didn't obtain necessary regulatory approvals within the deal's predetermined timeframe, even after the two parties had extended that deadline to Nov. 13.
Crown had originally planned to transfer all its shares to Miramar Lifesciences, itself a subsidiary of Adicon Holdings, before the parties mutually walked back the deal. Adicon is a Hangzhou-based network of medical laboratories that fits into the portfolio of the Carlyle Group global investment firm.
“There will be no changes to Crown Bioscience’s business operations or relationships with customers and partners as a result of this decision,” Crown said in the statement.
The relationship with Crown started nearly a year ago when Adicon agreed to pay $120 million up front for the CRO. The deal was valued at $204 million total, with payments of $40 million and $44 million to follow at the end of 2026 and the middle of 2028 if certain conditions were met.
Crown Biosciences, a subsidiary of JSR Life Sciences, is a global CRO that specializes in providing discovery, preclinical and translational platforms and services, such as bioinformatics solutions for drug validation and biomarker discovery. The oncology specialist boasts more than 1,000 tumor organoid models for studying drug targets for cancer, as well as locations across the U.S., Europe and Asia.
The CRO was originally bought by JSR in 2017 for $400 million to boost the contracting firm's global footprint and research operations.